Phase II trial of XmAb20717 (vudalimab) in patients with advanced biliary tract cancers

被引：0
|
作者：
Chapin, William Joseph [1 ]
Agarwal, Parul [1 ]
DiCicco, Lisa [1 ]
Palmer, Rayleigh [1 ]
Cenou, Nadia [1 ]
Huang, Alexander Chan Chi [1 ]
Karasic, Thomas Benjamin [1 ]
机构：
[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4184
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A multicenter phase II trial of rucaparib in combination with nivolumab as maintenance therapy for patients with advanced biliary tract cancer.
    Sahai, Vaibhav
    Tran, Nguyen H.
    Griffith, Kent A.
    Zalupski, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] EXIBIT:: An international multicenter phase II trial of gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer.
    André, T.
    Reyes-Vidal, J. M.
    Fartoux, L.
    Ross, P.
    Leslie, M.
    Rosmorduc, O.
    Clemens, M. R.
    Louvet, C.
    Perez, N.
    Scheithauer, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 211S - 211S
  • [43] IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer
    Hack, Stephen P.
    Verret, Wendy
    Mulla, Sohail
    Liu, Bo
    Wang, Yulei
    Macarulla, Teresa
    Ren, Zhenggang
    El-Khoueiry, Anthony B.
    Zhu, Andrew X.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [44] Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma
    von Delius, S
    Lersch, C
    Schulte-Frohlinde, ES
    Mayr, M
    Schmid, RM
    Eckel, F
    BMC CANCER, 2005, 5 (1)
  • [45] Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma
    Stefan von Delius
    Christian Lersch
    Ewert Schulte-Frohlinde
    Martina Mayr
    Roland M Schmid
    Florian Eckel
    BMC Cancer, 5
  • [46] Phase II trial of trifluridine/tipiracil (TAS-102) in patients with advanced refractory biliary tract cancer (BTC)
    Chakrabarti, S.
    Zemla, T.
    Ou, F-S.
    Fruth, B.
    Ahn, D.
    Borad, M. J.
    Hartgers, M. L.
    Wessling, J.
    Walkes, R. L.
    Alberts, S.
    McWilliams, R. R.
    Liu, M. C.
    Mahipal, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [47] Precision medicine for patients with advanced biliary tract cancers: Updated results from the prospective MOSCATO trial
    Verlingue, L.
    Malka, D.
    Allorant, A.
    Massard, C.
    Ferte, C.
    Lacroix, L.
    Rouleau, E.
    Auger, N.
    Delahousse, J.
    Sun, R.
    de Baere, T.
    Tselikas, L.
    Ba, B.
    Scoazec, J-Y.
    Michiels, S.
    Boige, V.
    Ducreux, M.
    Soria, J-C.
    Hollebecque, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] P Palliative management of malignant biliary obstruction in patients with advanced biliary tract cancers
    Berrad, S.
    Oualla, K.
    Nouikh, I.
    Frraichi, H.
    Messoudi, K.
    Mellas, N.
    Benbrahim, Z.
    ANNALS OF ONCOLOGY, 2019, 30
  • [49] Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial
    Kim, Seung Tae
    Oh, Sung Yong
    Lee, Jeeyun
    Kang, Jung Hun
    Lee, Hyun Woo
    Lee, Myung Ah
    Sohn, Byeong Seok
    Hong, Ji Hyong
    Park, Young Suk
    Park, Joon Oh
    Lim, Ho Yeong
    JOURNAL OF CANCER, 2019, 10 (25): : 6185 - 6190
  • [50] Phase II trial of hepatic arterial infusion chemotherapy plus bevacizumab and toripalimab for advanced biliary tract cancers: efficacy, safety, and exploratory analysis
    Zheng, Kanglian
    Fu, Shijie
    Zhu, Xu
    Cao, Guang
    Xu, Liang
    Liu, Peng
    Gao, Song
    Xu, Haifeng
    Guo, Jianhai
    Chen, Hui
    Liu, Wei
    Xu, Da
    Wang, Lijun
    Yan, Xiaoluan
    Bao, Quan
    Wu, Jianhui
    Wang, Kun
    Zhou, Jun
    Hao, Chunyi
    Xing, Baocai
    Shen, Lin
    Yang, Renjie
    Wang, Xiaodong
    HEPATOBILIARY SURGERY AND NUTRITION, 2025,
12345